Feb 19, 2026 | Press Releases
Leadership Enhancements Position Company for Upcoming Regulatory Engagement and Clinical MilestonesNew Appointments Reinforce Operational Readiness Across Finance, Regulatory Affairs and Program LeadershipKing of Prussia, Pennsylvania–(Newsfile Corp. –...
Feb 10, 2026 | Press Releases
Maximum Dose Concentration in Final Cohort Yields 85% Pathological Response (6 of 7 Patients); Complete Response (100% Tumor Clearance) in 4 of 6 RespondersNo Serious Adverse Events or Dose-Limiting Toxicities Identified Across All 5 Dose Escalation CohortsKing of...
Jan 26, 2026 | Press Releases
Phio’s Presentation to take place on Wednesday January 28, 2026 at 9 AM ETKing of Prussia, Pennsylvania–(Newsfile Corp. – January 26, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company...
Jan 20, 2026 | Press Releases
Pathology data indicate 70% overall response rate for squamous cell carcinomas: 100% clearance in 10 out of 14 responders Favorable safety and tolerability at all dose escalations King of Prussia, Pennsylvania–(Newsfile Corp. – January 20, 2026) –...
Jan 15, 2026 | Press Releases
Registration Link for Phio’s Presentation on Thursday, January 22 at 1:45 PM ETKing of Prussia, Pennsylvania–(Newsfile Corp. – January 15, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company...
Dec 23, 2025 | Press Releases
Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania–(Newsfile Corp. – December 23, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
